NCT06998095Not yet recruiting
Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea
Source: ClinicalTrials.gov · Last updated 4 Jun 2026
Brief summary (registry, in English)
The objectives of this study are to describe the incidence of adverse events and the effectiveness of tezepelumab in patients receiving tezepelumab as indicated for severe asthma or CRSwNP in South Korea.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 210 (estimated)
- First submitted
- 29 May 2025
- Start date
- 28 Nov 2026
- Primary completion date
- 31 Oct 2029
- Lead sponsor
- AstraZeneca
- Diseases
- Asthma
- NCT number
- NCT06998095
What you commit to
- Study type: Observational
- Planned participants: 210
- From 28 Nov 2026 to the primary completion date, 31 Oct 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Other off-label indications according to the locally approved prescribing information
- Current participation in any interventional trial
Who the study is looking for
- Patients who are treated with at least one dose of tezepelumab according to the indication in the locally approved prescribing information
- Patients with evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study
Age in the registry: 12 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.